Skip to main content
Top
Published in: Graefe's Archive for Clinical and Experimental Ophthalmology 6/2008

01-06-2008 | Retinal Disorders

Activity of neovascular lesions treated with bevacizumab: comparison between optical coherence tomography and fluorescein angiography

Authors: Ilse Krebs, Siamak Ansari-Shahrezaei, Alexandra Goll, Susanne Binder

Published in: Graefe's Archive for Clinical and Experimental Ophthalmology | Issue 6/2008

Login to get access

Abstract

Purpose

To investigate whether examination with the non-invasive optical coherence tomography (OCT) alone is sufficient to ascertain the need of re-treatment with bevacizumab for exudative age-related macular degeneration (AMD) or the invasive fluorescein angiography (FA) is needed.

Method

Two independent examiners reviewed FA and OCT images and performed a semi-quantitative assessment from 0=no activity to activity 1–3, mild, moderate and advanced, respectively. Weighted Kappa indices were performed to calculate the concordance between OCT and FA.

Results

A total of 153 OCT and FA examinations of 69 patients were evaluated, mean 2.2 examinations per patient. The mean age was 77.1±7.9 (55–89) years; 29.0% were male, 71.0% female. The weighted Kappa index showed concordance for activity in OCT and FA weak concerning the first investigation 4–6 weeks after initial treatment (0.3847) and obvious concerning the second investigation 8–10 weeks after initial treatment (0.4170). Higher values of activity were found with the OCT compared to FA. The most frequent reasons for discrepancies were detachment of the pigmentepithelium and fibrosis.

Conclusion

There is evidence of agreement between both examinations, the OCT was even more sensitive to detect activity of a lesion. In conducting studies based on OCT as single examination, it should be clearly defined how long fibrotic lesions or lesions with pigment epithelial detachment should be re-treated.
Literature
1.
go back to reference Avery RL, Pieramici DJ, Rabena MD et al (2006) Intravitreal bevacizumab (Avastin) for neovascular age-related macular degeneration. Ophthalmology 113:363–372PubMedCrossRef Avery RL, Pieramici DJ, Rabena MD et al (2006) Intravitreal bevacizumab (Avastin) for neovascular age-related macular degeneration. Ophthalmology 113:363–372PubMedCrossRef
2.
go back to reference Bashshur ZF, Bazarbachi A, Schakal A et al (2006) Intravitreal bevacizumab for the management of choroidal neovascularization in age-related macular degeneration. Am J Ophthalmol 142:1–9PubMedCrossRef Bashshur ZF, Bazarbachi A, Schakal A et al (2006) Intravitreal bevacizumab for the management of choroidal neovascularization in age-related macular degeneration. Am J Ophthalmol 142:1–9PubMedCrossRef
3.
go back to reference Bressler NM, Treatment of Age-Related Macular Degeneration with Photodynamic Therapy (TAP) Study Group (2001) Photodynamic therapy of subfoveal choroidal neovascularization in age-related macular degeneration with verteporfin: two-year results of 2 randomized clinical trials-tap report 2. Arch Ophthalmol 119:198–207PubMed Bressler NM, Treatment of Age-Related Macular Degeneration with Photodynamic Therapy (TAP) Study Group (2001) Photodynamic therapy of subfoveal choroidal neovascularization in age-related macular degeneration with verteporfin: two-year results of 2 randomized clinical trials-tap report 2. Arch Ophthalmol 119:198–207PubMed
4.
go back to reference Fung AE, Lalwani GA, Rosenfeld PJ et al (2007) An optical coherence tomography-guided, variable dosing regimen with intravitreal ranibizumab (Lucentis) for neovascular age-related macular degeneration. Am J Ophthalmol 143:566–583PubMedCrossRef Fung AE, Lalwani GA, Rosenfeld PJ et al (2007) An optical coherence tomography-guided, variable dosing regimen with intravitreal ranibizumab (Lucentis) for neovascular age-related macular degeneration. Am J Ophthalmol 143:566–583PubMedCrossRef
5.
go back to reference Holz FG, Jorzik J, Schutt F et al (2003) Agreement among ophthalmologists in evaluating fluorescein angiograms in patients with neovascular age-related macular degeneration for photodynamic therapy eligibility (FLAP-study). Ophthalmology 110:400–405PubMedCrossRef Holz FG, Jorzik J, Schutt F et al (2003) Agreement among ophthalmologists in evaluating fluorescein angiograms in patients with neovascular age-related macular degeneration for photodynamic therapy eligibility (FLAP-study). Ophthalmology 110:400–405PubMedCrossRef
6.
go back to reference Krebs I, Binder S, Stolba U et al (2005) Optical coherence tomography guided retreatment of photodynamic therapy. Br J Ophthalmol 89:1184–1187PubMedCrossRef Krebs I, Binder S, Stolba U et al (2005) Optical coherence tomography guided retreatment of photodynamic therapy. Br J Ophthalmol 89:1184–1187PubMedCrossRef
7.
go back to reference Macular Photocoagulation Study Group (1991) Subfoveal neovascular lesions in age-related macular degeneration. Guidelines for evaluation and treatment in the macular photocoagulation study. Arch Ophthalmol 109:1242–1257 Macular Photocoagulation Study Group (1991) Subfoveal neovascular lesions in age-related macular degeneration. Guidelines for evaluation and treatment in the macular photocoagulation study. Arch Ophthalmol 109:1242–1257
8.
go back to reference Moshfeghi AA, Rosenfeld PJ, Puliafito CA et al (2006) Systemic bevacizumab (Avastin) therapy for neovascular age-related macular degeneration: twenty-four-week results of an uncontrolled open-label clinical study. Ophthalmology 113:2002.e1–e12 Moshfeghi AA, Rosenfeld PJ, Puliafito CA et al (2006) Systemic bevacizumab (Avastin) therapy for neovascular age-related macular degeneration: twenty-four-week results of an uncontrolled open-label clinical study. Ophthalmology 113:2002.e1–e12
9.
go back to reference Rich RM, Rosenfeld PJ, Puliafito CA et al (2006) Short-term safety and efficacy of intravitreal bevacizumab (Avastin) for neovascular age-related macular degeneration. Retina 26:495–511PubMedCrossRef Rich RM, Rosenfeld PJ, Puliafito CA et al (2006) Short-term safety and efficacy of intravitreal bevacizumab (Avastin) for neovascular age-related macular degeneration. Retina 26:495–511PubMedCrossRef
10.
go back to reference Sandhu SS, Talks SJ (2005) Correlation of optical coherence tomography, with or without additional colour fundus photography, with stereo fundus fluorescein angiography in diagnosing choroidal neovascular membranes. Br J Ophthalmol 89:967–970PubMedCrossRef Sandhu SS, Talks SJ (2005) Correlation of optical coherence tomography, with or without additional colour fundus photography, with stereo fundus fluorescein angiography in diagnosing choroidal neovascular membranes. Br J Ophthalmol 89:967–970PubMedCrossRef
11.
go back to reference Talks SJ, Koshy ZR, Chatzinikolas K (2007) The use of optical coherence tomography, flourescein angiography and indocyanine green angiography in a screening clinic for wet age-related macular degeneration. Br J Ophthalmol 91:600–601PubMedCrossRef Talks SJ, Koshy ZR, Chatzinikolas K (2007) The use of optical coherence tomography, flourescein angiography and indocyanine green angiography in a screening clinic for wet age-related macular degeneration. Br J Ophthalmol 91:600–601PubMedCrossRef
12.
go back to reference Treatment of Age-Related Macular Degeneration with Photodynamic Therapy (TAP) Study Group (1999) Photodynamic therapy of subfoveal choroidal neovascularization in age-related macular degeneration with verteporfin: one-year results of 2 randomized clinical trials-TAP report. Arch Ophthalmol 117:1329–1345 Treatment of Age-Related Macular Degeneration with Photodynamic Therapy (TAP) Study Group (1999) Photodynamic therapy of subfoveal choroidal neovascularization in age-related macular degeneration with verteporfin: one-year results of 2 randomized clinical trials-TAP report. Arch Ophthalmol 117:1329–1345
13.
go back to reference Verteporfin Roundtable Participants (2005) Guidelines for using verteporfin (Visudyne) in photodynamic therapy for choroidal neovascularization due to age-related macular degeneration and other causes: update. Retina 25(2):119–134, Feb–MarCrossRef Verteporfin Roundtable Participants (2005) Guidelines for using verteporfin (Visudyne) in photodynamic therapy for choroidal neovascularization due to age-related macular degeneration and other causes: update. Retina 25(2):119–134, Feb–MarCrossRef
14.
go back to reference Yoganathan P, Deramo VA, Lai JC et al (2006) Visual improvement following intravitreal bevacizumab (Avastin) in exudative age-related macular degeneration. Retina 26:994–998PubMedCrossRef Yoganathan P, Deramo VA, Lai JC et al (2006) Visual improvement following intravitreal bevacizumab (Avastin) in exudative age-related macular degeneration. Retina 26:994–998PubMedCrossRef
Metadata
Title
Activity of neovascular lesions treated with bevacizumab: comparison between optical coherence tomography and fluorescein angiography
Authors
Ilse Krebs
Siamak Ansari-Shahrezaei
Alexandra Goll
Susanne Binder
Publication date
01-06-2008
Publisher
Springer-Verlag
Published in
Graefe's Archive for Clinical and Experimental Ophthalmology / Issue 6/2008
Print ISSN: 0721-832X
Electronic ISSN: 1435-702X
DOI
https://doi.org/10.1007/s00417-007-0755-6

Other articles of this Issue 6/2008

Graefe's Archive for Clinical and Experimental Ophthalmology 6/2008 Go to the issue